dyadic.com (DYAI) Company Gross Revenue

Corporate emblem and logo of Dyadic International, Inc. (DYAI)

Sales performance dynamics for Dyadic International (DYAI) confirm the effectiveness of the C1 platform management in extracting profit from patents. The value of 0.00 represents the current realization rate. Stable B2B relationships in the vaccine sector and expansion into agritech are strengthening the ecosystem. However, geopolitical risks and the potential cancellation of licenses during conflict periods pose threats to the supply chains of active substances.

Dyadic International Inc - DYAI Company Sales (period 07/04/2022 - 11/13/2026)

Comprehensive metric breakdowns and analytics for Dyadic International Inc (DYAI)

- price and consensus price forecast:
Stock Price Dyadic|DYAI - Price Target Chart
- market capitalization details:
Market Capitalization Dyadic International, Inc.|DYAI - Enterprise Value
- book capitalization data:
Equity per Share Dyadic International|DYAI - Company Net Assets|Market-to-Book Ratio dyadic.com|DYAI - Company Total Assets
- debt and solvency information:
Total Debt to Capital Dyadic International|DYAI - Long-Term Debt to Capital|Short-Term Debt to Capital Ratio Dyadic|DYAI - Company Aggregate Debts|Debts to Net Assets Dyadic International, Inc.|DYAI - Company Long-Term Debts|Company Current Liabilities Dyadic International|Intermediate Coverage Ratio dyadic.com
- financial results and valuation multiples details:
DYAI - Net Profit|Company Profit Forecast Dyadic International|DYAI - Price to Earnings Ratio|Price to Future Earnings Ratio Dyadic|DYAI - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Dyadic International, Inc.|DYAI - Operating profit EBITDA|Net earnings per one share for the last twelve months Dyadic International|DYAI - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months dyadic.com|DYAI - Earnings per share growth in current year|Projected earnings per share growth rate for next year Dyadic International
- issuer revenue and sales details:
DYAI - Revenue and Sales Volume|Projected Sales Volume Dyadic|DYAI - Market Cap to Revenue|Price to Expected Revenue Ratio Dyadic International, Inc.
Summary company analysis:Dyadic International
Core merchandise of dyadic.com

Selecting assets with a high margin of safety begins with an analysis of real cash flows. This indicator captures actual sales revenue, reflecting the balance between operational business reliability and market risks. For Dyadic International (DYAI), this represents the volume of payments for licensing the C1 fungal platform in vaccine production. The dynamics of these inflows determine the company's sales growth rate, visualizing the effectiveness of its intellectual property monetization.

Key competitors

Revenue and Sales Volume Gilead Corp|Company Revenue Cidara (CDTX)|Company Gross Revenue novavax.com|Revenue and Sales Volume CVAC (CureVac)|VALN: Company Sales Volume|VIR: Company Sales|Company Total Revenue TPOXX|EBS: Revenue and Sales Volume|ateapharma.com (AVIR) - Revenue and Sales Volume|IVVD (Invivyd Inc) - Revenue and Sales Volume|Company Sales Volume ENTA (Enanta Pharmaceuticals Inc.)|Revenue and Sales Volume INO|Company Gross Revenue HilleVax Inc.|Revenue and Sales Volume KLRS (Kalaris Therapeutics Inc)|NNVC - Company Sales|TLPH: Company Sales|Company Sales Revenue COCP (Cocrystal Pharma Inc)|TRAW: Revenue and Sales Volume|DWTX - Company Gross Revenue|Company Revenue Qualigen Therapeutics|Company Sales Volume ALVR (AlloVir Bio)|Company Sales VBIV (VBI Vaccines Inc.)|Company Total Sales VIRI|Revenue and Sales Volume VXRT (Vaxart)